Ralf Marienfeld
Overview
Explore the profile of Ralf Marienfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schulte L, Schulte , Beck A, Marienfeld R, Azoitei N, Barth T, et al.
J Pathol
. 2025 Feb;
265(4):401-407.
PMID: 39906959
Pancreatic ductal adenocarcinoma (PDAC) often arises from preexisting cystic lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN). This study investigated the molecular heterogeneity and mutational...
2.
Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):37.
PMID: 39820556
Background: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the...
3.
Dugge R, Weissinger S, Marienfeld R, Moller P, Barth T
Ann Hematol
. 2024 Dec;
103(12):6057-6058.
PMID: 39663255
No abstract available.
4.
Maier J, Schwab J, Werle S, Marienfeld R, Moller P, Gaisa N, et al.
Pathologie (Heidelb)
. 2024 Nov;
45(Suppl 1):26-30.
PMID: 39535613
The limited availability of suitable animal models and cell lines often impedes experimental cancer research. Wet-laboratory experiments are also time-consuming and cost-intensive. In this review, we present an in silico...
5.
Gaidzik V, Mayer-Steinacker R, Wittau M, Schultheiss M, V Baer A, Oehl-Huber K, et al.
Sarcoma
. 2024 Oct;
2024:5036102.
PMID: 39411551
Desmoplastic small round blue cell tumor (DSRCT) is a highly aggressive fatal sarcoma without evidence-based therapeutic guidelines. We present here seven patients with DSRCT including immunohistochemistry combined with fluorescence in...
6.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, et al.
Eur J Cancer
. 2024 Sep;
211:114306.
PMID: 39293347
Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust...
7.
Bette S, Haase L, Nell J, Grieser T, von Baer A, Schultheiss M, et al.
Diagnostics (Basel)
. 2024 May;
14(10).
PMID: 38786326
Chordomas are very rare malignant neoplasms of the bone occurring almost exclusively along the spine. As the tumours are thought to arise from notochordal remnants, the vast majority of chordomas...
8.
Kumbrink J, Demes M, Jeroch J, Brauninger A, Hartung K, Gerstenmaier U, et al.
Pathol Oncol Res
. 2024 Apr;
30:1611590.
PMID: 38605929
Lung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation...
9.
Kolb T, Muller S, Moller P, Barth T, Marienfeld R
Neoplasia
. 2024 Feb;
49:100955.
PMID: 38310709
Lung cancer is the leading cause in cancer related death, with non-small cell lung cancer (NSCLC) being the most frequent subtype. The importance of NSCLC is reflected by the various...
10.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):106.
PMID: 37864096
A growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire...